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Myelocytomatosis viral oncogene homolog (MYC) plays an important role
in the regulation of many cellular processes, and its expression is tightly
regulated at the level of transcription, translation, protein stability, and
activity. Despite this tight regulation, MYC is overexpressed in many can-
cers and contributes to multiple hallmarks of cancer. In recent years, it has
become clear that noncoding RNAs add a crucial additional layer to the
regulation of MYC and its downstream effects. So far, twenty-five micro-
RNAs and eighteen long noncoding RNAs that regulate MYC have been
identified. Thirty-three miRNAs and nineteen lncRNAs are downstream
effectors of MYC that contribute to the broad oncogenic role of MYC,
including its effects on diverse hallmarks of cancer. In this review, we give
an overview of this extensive, multilayered noncoding RNA network that
exists around MYC. Current data clearly show explicit roles of crosstalk
between MYC and ncRNAs to allow tumorigenesis.
1. Introduction
The MYC gene family consist of three members, that
is, c-MYC, n-MYC, and l-MYC. c-MYC forms a
central hub in all cells by regulating many cellular pro-
cesses, while n-MYC and l-MYC are more tissue-speci-
fic regulators. MYC proteins are overexpressed in
more than half of all human cancers, including lung,
breast, and colon cancers (Albihn et al., 2010). This
overexpression is caused by diverse mechanisms
including amplifications, translocations, and epigenetic
alterations (Kalkat et al., 2017). In this review, we will
focus on c-MYC, hereafter referred to as MYC.
MYC belongs to the basic helix–loop–helix superfam-
ily and functions as a transcription factor. Upon dimer-
ization with its binding partner MAX, the MYC-MAX
dimer binds to E-box sequences in the promoter region
of its targets genes, thereby activating transcription of
these genes (Tu et al., 2015). In addition to interacting
with MAX, MYC can also interact with other tran-
scription factors, histone-modifying enzymes, and DNA
methyltransferases to repress transcription. MYC regu-
lates the transcription of many different genes, which
include protein-coding as well as noncoding genes
(Dang, 2012; Hart et al., 2014; Winkle et al., 2015).
These noncoding genes can include various RNA mole-
cules, for example, miRNAs and lncRNAs.
miRNAs are noncoding, regulatory RNA molecules
of about 22 nucleotides in length. A miRNA is tran-
scribed as a longer primary transcript, which is pro-
cessed in two steps into a mature single-stranded
miRNA and subsequently incorporated into the RISC.
The miRNA guides the RISC complex to its target
mRNA by recognition of a complementary sequence,
most often in the 30 UTR. Usually, conserved Wat-
son–Crick pairing with nucleotides 2–7 of the miRNA,
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the so-called seed region, is essential for target recogni-
tion (Bartel, 2009). Binding to the target mRNA will
subsequently result in mRNA cleavage by AGO2 in
case the miRNA has high complementarity with the
binding site region on the mRNA. In case of a low
level of complementarity, binding will lead to transla-
tional repression.
LncRNAs are defined as noncoding RNA molecules
of more than 200 nucleotides in length. Their expression
is often tissue specific or cell type specific, and their tran-
scripts can have subcellular compartment-specific local-
izations. Together, this restricts their function to specific
cell types and locations. LncRNAs can regulate gene
expression at the transcriptional and post-transcrip-
tional level, as well as by modulating protein stability,
localization, and functionality via diverse mechanisms.
In the nucleus, lncRNAs can regulate transcription of
nearby genes in cis or of more distant genes in trans, for
example, by recruiting transcription factors, chromatin-
modifying complexes, or heterogeneous nuclear ribonu-
cleoprotein (hnRNP) complexes. LncRNAs residing in
the cytoplasm can modulate mRNA stability, transla-
tion efficiency, or protein stability, localization, or
activity. Cytoplasmic lncRNAs can act as decoys to
sequester RNA binding proteins or miRNAs (sponges
or ceRNAs) or interfere with post-translational modifier
proteins (Chen, 2016; Schmitt and Chang, 2016).
Over the last decades, it has become clear that MYC
is not only regulated by and regulates many protein-
coding genes, but this extensive network also includes
the family of ncRNAs. The overall aim of this review
was to present an overview of the intricate crosstalk
between ncRNAs and MYC. We first focus on
ncRNAs acting upstream of MYC by regulating its
transcription, translation, and activity. In addition, we
focus on ncRNAs acting downstream of MYC and pin-
point their contributions to crucial hallmarks of cancer.
2. ncRNAs regulating MYC
2.1. miRNAs regulating MYC
In total, twenty-five miRNAs belonging to twenty dif-
ferent seed families have been described to directly reg-
ulate MYC (Fig. 1). Most of the miRNAs bind to the
MYC transcript in a canonical fashion, that is, with
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so-called seed-containing binding sites in the 30UTR.
Binding of let-7b/c-5p is enhanced by adjacent binding
of the RNA-binding protein HuR, which makes the
miRNA binding site accessible (Kim et al., 2009). One
of the two miR-24-3p binding sites is seed-containing,
while the other less-efficient site is ‘seedless’ and has
extensive complementarity at the 30-end of the miRNA
(Lal et al., 2009). MiR-17-5p was shown to bind to
the 50 UTR of the MYC mRNA (Liu et al., 2016),
while miR-184-3p (Zhen et al., 2013), miR-185-3p
(Liao and Liu, 2011), miR-320b-3p (Wang et al.,
2015), and miR-744-5p (Lin et al., 2014) bind to the
MYC ORF.
Next to regulating MYC in a direct fashion, miR-
24-3p can also influence MYC protein levels indirectly
by targeting OGT. OGT can O-GlcNAcylate the
MYC protein and thereby increase its stability (Liu
et al., 2017). A second miRNA that can act indirectly
on MYC is miR-375-3p, which targets CIP2A. CIP2A
prevents phosphorylation of Ser62 on MYC by PP2A
and thereby prevents degradation of MYC (Jung
et al., 2013). So, miR-24-3p and miR-375-3p can
downregulate MYC protein levels indirectly by target-
ing OGT and CIP2A, respectively.
Many of the miRNAs that can directly downregu-
late MYC by binding to the MYC mRNA, show
reduced levels in cancer. The decreased expression of
these miRNAs can thus contribute to the high levels
of MYC as commonly observed in cancer. Examples
are the let-7-5p family, miR-148a-5p, miR-331-3p, and
miR-363-3p, which are downregulated in Burkitt lym-
phoma compared to normal lymph nodes (Bueno
et al., 2011). A well-known exception is miR-17-5p,
which is part of the oncogenic miR-17~92 cluster that
is often upregulated in MYC-driven cancers. As too
high MYC levels are potentially dangerous for cancer
cells, targeting of MYC by miR-17-5p may be a means
to maintain optimal MYC levels and sustain continu-
ous tumor growth (Liu et al., 2016).
2.2. lncRNAs regulating MYC
Expression of MYC is controlled at the level of tran-
scription, translation, and protein stability. Several
lncRNAs have been demonstrated to play a role in
these regulatory processes. Here, we describe the
lncRNAs with a well-characterized role in MYC regu-
lation (Fig. 2).
2.2.1. LncRNAs regulating MYC transcription in cis
Besides the MYC gene, the 8q24 region harbors sev-
eral noncoding genes that can regulate MYC transcrip-
tion. CCAT1-L transcript variant of the CCAT1 gene
and CCAT2 are specifically expressed in colorectal
cancer (Ling et al., 2013; Xiang et al., 2014). CCAT1-
L is a nuclear lncRNA that accumulates in distinct
nuclear foci near its site of transcription. Knockdown
of CCAT1-L reduced, while overexpression enhanced
transcription of MYC in cis. This regulatory effect on
MYC was attributed to the spatial proximity of the
CCAT1-L locus with the MYC promoter. Indeed,
reduced chromatin loop formation between the
CCAT1-L and MYC loci was observed upon knock-
down of CCAT1-L transcription. The loop formation
was dependent on interaction of CCAT1-L with
CTCF, which enhanced binding of CTCF to the MYC



























































































































Fig. 1. miRNA-binding sites on the MYC mRNA. Schematic representation of the MYC mRNA with the binding sites of the MYC-regulating
miRNAs indicated. Only miRNAs for which binding to the mRNA was proven at least by reporter assay have been implemented in the
figure. The miRNAs let-7a/b/c/e/f-5p and miR-98-5p of the let-7 family (Bueno et al., 2011; Kim et al., 2009), miR-24-3p (Lal et al., 2009),
miR-33b-5p (Takwi et al., 2012), miR-34a/c-5p (Christoffersen et al., 2010; Kong et al., 2008), miR-145-5p (Sachdeva et al., 2009), miR-135b-
5p (Liu et al., 2014), miR-148a-5p (Han et al., 2013), miR-182a-5p (Huang et al., 2017), miR-331-3p (Bueno et al., 2011), miR-363-3p (Bueno
et al., 2011), miR-449c-5p (Miao et al., 2013), miR-451-5p (Li et al., 2011), miR-494-3p (Zhang et al., 2012b), and miR-1294-5p (Liu et al.,
2015a) target the MYC mRNA by binding to its 30 UTR, while miR-17-5p binds to the 50 UTR (Liu et al., 2016) and miR-184-3p (Zhen et al.,
2013), miR-185-3p (Liao and Liu, 2011), miR-320b-3p (Wang et al., 2015), and miR-744-5p (Lin et al., 2014) bind to the MYC ORF.
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enhancing the activity of TCF7L2, a transcription fac-
tor for MYC (Ling et al., 2013). Thus, both CCAT1-L
and CCAT2 positively regulate MYC transcription.
Interaction between an enhancer region down-
stream the first transcriptional start site of PVT1 and
the PVT1 promoter itself has tumor suppressor activ-
ity by reducing MYC transcription (Cho et al., 2018).
Silencing of the PVT1 promoter increased MYC
expression independent of the PVT1 transcript itself.
The underlying mechanism has been identified as a
competition between the PVT1 promoter and the
MYC promoter for interaction with the intragenic
enhancer region in the PVT1 locus. Under normal
conditions, these enhancers preferentially bind to the
PVT1 promoter. Silencing of the PVT1 promoter
allowed interaction of enhancers with the MYC pro-
moter, leading to increased MYC transcription.
Importantly, this effect is restricted to cells where
MYC forms chromatin loops with PVT1, for exam-















































Fig. 2. lncRNAs regulating MYC at the DNA, mRNA, or protein levels. LncRNAs and their interaction partners involved in regulation of MYC
transcription, translation, stability, and functionality at protein level are indicated. The genomic region around MYC and the MYC mRNA
(central thick and curved gray line) are not drawn to scale. LncRNAs are indicated by curved lines and proteins by ellipses. LncRNAs
highlighted in blue indicate that they stimulate and lncRNA highlighted in yellow indicate that they repress MYC transcription, translation,
stability, or functionality, and the arrows indicate stimulating or repressing effects on MYC.
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cervical carcinoma cells where MYC loops to the
CCAT1 enhancer.
The levels of three partially overlapping lncRNA
transcripts antisense to the 30 distal region of MYC,
NAT6531, NAT6538, and NAT7281, are regulated
by histone H3 acetylation in prostate cancer cells.
Under normal conditions, NAT6531 is expressed and
processed by DICER into several short RNAs,
which have a repressive effect on MYC transcrip-
tion, possibly by binding to the MYC promoter and
intron 1 through partial sequence complementarity.
Partial inhibition of histone deacetylation shifts tran-
scription from NAT6531 to NAT6538, and this
releases the block on MYC transcription. Strong
inhibition of histone deacetylation results in tran-
scription of the longer NAT7281, which strongly
represses MYC transcription (Napoli et al., 2017).
2.2.2. LncRNAs controlling MYC mRNA stability and
translation
IGF2BPs enhance mRNA stability and promote trans-
lation by binding to the MYC mRNA (Huang et al.,
2018). A number of cell type-specific lncRNAs have
been identified that modulate this interaction. Interac-
tion of IGF2BP1 with lncRNA GHET1 in gastric can-
cer and THOR in renal and skin cancer increased
MYC mRNA and protein levels (Liu et al., 2018;
Yang et al., 2014; Ye et al., 2018). In contrast, binding
of the skeletal muscle-specific lncRNA lncMyoD to
IGF2BP2 decreased MYC mRNA levels by preventing
binding of IGF2BP2 to MYC mRNA (Gong et al.,
2015).
Binding of AUF1 to an ARE site in the 30UTR of
the MYC transcript can both positively and negatively
affect MYC levels, depending on the cell-type. In nor-
mal kidney cells, FILNC1 acts as a decoy for AUF1
preventing binding of AUF1 to the MYC mRNA,
thereby resulting in low MYC protein levels. In renal
cancer, FILNC1 is downregulated, resulting in an
AUF1-dependent increase in MYC protein levels
(Xiao et al., 2017). In breast and colon cancers, bind-
ing of linc-RoR to AUF1 inhibits binding of AUF1 to
MYC mRNA and thereby increases MYC levels
(Huang et al., 2015). It is currently unclear why
sequestering of AUF1 has opposite effects on MYC
levels in these different cell types. In addition, linc-
RoR facilitates binding of RNA binding protein
hnRNP-I to MYC mRNA and this also enhances
MYC protein levels.
MYC can be translated using an IRES in case the
regular cap-dependent translation is compromised.
This requires binding of the IRES trans-acting factors
PSF and p54nrb (Cobbold et al., 2008). These factors
are sequestered by lncRNA NEAT1 to the paraspeck-
les. In HeLa cells, depletion of NEAT1 during nucleo-
lar stress released PSF and p54nrb from paraspeckles
and allowed IRES-dependent translation of MYC
(Shen et al., 2017).
LncRNAs can also stimulate MYC mRNA transla-
tion by competing with MYC-regulating miRNAs.
This has been shown for PCAT-1, which competes
with miR-34a-5p for interaction with its binding site in
the 30 UTR of the MYC mRNA (Prensner et al.,
2011, 2014). The effect of PCAT-1 can be antagonized
by miR-3667-3p, which targets PCAT-1.
2.2.3. LncRNAs affecting MYC protein stability and
activity
The stability of MYC protein can be increased by two
lncRNAs that both prevent its degradation, but via
distinct mechanisms. In contrast to the tumor-suppres-
sive role of the PVT1 promoter, the PVT1 transcript
can act as an oncogene. PVT1 stabilizes the MYC pro-
tein by preventing phosphorylation of threonine 58,
which is a signal for its degradation (Tseng et al.,
2014). LINC01638 prevents MYC protein degradation
by preventing binding of E3 ubiquitin ligase adapter
SPOP to MYC (Luo et al., 2018).
Three lncRNAs modulate interaction of MYC with
(subsets of) its target genes by directly binding to
MYC. PCGEM1 is a prostate-specific lncRNA, which
together with MYC co-occupies the promoter regions
of several metabolic genes documented to be MYC
targets. Knockdown of PCGEM1 reduced recruitment
of MYC to the promoters of these PCGEM1-depen-
dent metabolic genes without affecting MYC protein
levels (Hung et al., 2014). Thus, PCGEM1 affects the
metabolic state of cancer cells by enhancing MYC
occupancy at the promoters of several metabolic genes.
LncRNA PDIA3P regulates the metabolic state of
multiple myeloma cells via induction of G6PD, an
enzyme crucial for promoting the PPP flux (Yang
et al., 2018). This effect is achieved by interaction of
PDIA3P with MYC and promoting MYC binding to
the G6PD promoter. Together with MYC, lncRNA
EPIC1 co-occupies the promoters of > 97% of EPIC1-
regulated genes involved in cell cycle progression, and
thereby regulates transcriptional activity of these genes
in breast cancer cells (Wang et al., 2018).
From the studies presented here, lncRNAs emerge
as important regulators of MYC expression and activ-
ity, either directly or indirectly by interacting with pro-
teins. Often, these lncRNAs are deregulated in cancer
and promote high MYC levels and activity. Since
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expression of lncRNAs is highly cell type specific,
many of the lncRNA-MYC interactions are restricted
to certain tissues. Future studies will likely broaden
the repertoire of lncRNAs regulating MYC and
improve the understanding of the underlying mecha-
nisms in normal and cancer cells.
2.3. Feedback loops on MYC
Next to the more straightforward regulation of MYC
by ncRNAs as described above, more complex feed-
back loops between MYC and MYC-regulating
ncRNAs have been identified. These include feedback
loops that involve MYC-regulated miRNAs, as well as
MYC-regulated lncRNAs that act as sponges for
MYC-regulating miRNAs.
2.3.1. Feedback loops involving MYC-regulated
miRNAs
Several miRNAs that regulate MYC can be induced
or repressed by MYC as well, resulting in the forma-
tion of feedback loops. Examples of this are the feed-
back loops between MYC and MYC-induced miR-7-
5p (Capizzi et al., 2017; Chou et al., 2010), miR-17-5p
(Liu et al., 2016), and miR-185-3p (Liao and Liu,
2011). For miR-7-5p, a positive feedback loop is
formed via the miR-7-5p target AMBRA1, which pro-
motes dephosphorylation of Ser62 on MYC upon
binding to PP2A. This leads to stimulation of proteo-
somal degradation of MYC (Capizzi et al., 2017; Cian-
fanelli et al., 2015). In this way, miR-7-5p indirectly
enhances MYC protein stability and promotes its own
MYC-mediated transcription. MiR-17-5p and miR-
185-3p were shown to directly target MYC mRNA
resulting in a negative feedback loop (Liao and Liu,
2011; Liu et al., 2016).
Positive feedback loops that result in sustaining high
MYC expression also involve MYC-repressed miR-
NAs. Let-7a-5p, miR-34a-5p, miR-148a-5p, miR-363-
3p, and miR-451-5p are examples of MYC-repressed
miRNAs that can directly repress MYC translation
(Bommer et al., 2007; Bueno et al., 2011; Christof-
fersen et al., 2010; Ding et al., 2018; Han et al., 2013;
Sampson et al., 2007). Besides MYC, miR-363-3p also
targets USP28, a de-ubiquitinase involved in MYC sta-
bilization (Han et al., 2013). MiR-22 forms a feedback
loop with MYC by targeting the MYCBP transcript,
which encodes a positive regulator of MYC transcrip-
tional activity (Xiong et al., 2010). In hepatocellular
carcinoma, repression of liver-specific miR-122-5p
results in derepression of the miR-122 targets E2F1
and its interaction partner TFDP2 (Wang et al., 2014).
Both targets are involved in the induction of MYC
transcription, creating another feedback loop. MiR-
200b-3p participates in a feedback loop that involves
MYC protein stability by targeting Akt2 mRNA (Lv
et al., 2017). Akt2 represses the activity of GSK3b, an
enzyme that destabilizes the MYC protein by phos-
phorylation of threonine residue 58. Thus, by repress-
ing miR-200b-3p, MYC ensures inhibition of GSK3b,
thereby stimulating its own stability. In contrast,
MYC-repressed miR-30a-5p is involved in a negative
feedback loop by targeting UBE3C mRNA, a protein
that can ubiquitinate MYC for proteosomal degrada-
tion (Chang et al., 2008; Xiong et al., 2016).
2.3.2. Feedback loops involving MYC-regulated
lncRNAs acting as miRNA sponges
The functions of several MYC-regulating miRNAs can
be antagonized by MYC-regulated lncRNAs, which
act as sponges. By sequestering those miRNAs, the
following MYC-induced lncRNAs ensure high MYC
levels and create a positive feedback loop on MYC:
CCAT1-S, the short isoform of CCAT1-L (let-7a/b/c/
e-5p) (Deng et al., 2015), DANCR (miR-33b-5p) (Ma
et al., 2018), H19 (let-7a/b-5p) (Peng et al., 2017; Zhou
et al., 2017), linc00176 (miR-185-5p) (Tran et al.,
2017), and SNHG3 (miR-182a-5p) (Huang et al.,
2017). Another lncRNA that ensures high MYC levels
by sequestering miRNAs of the let-7-5p family without
being regulated by MYC is lincRNA CCR492 (Mal-
dotti et al., 2016). In contrast, the MYC-induced
lncRNA-MIF reduces MYC levels and creates a nega-
tive feedback loop by sequestering miR-586 (Zhang
et al., 2016a). This miRNA targets the mRNA encod-
ing E3 ubiquitin ligase Fbxw7, which stimulates MYC
degradation. Although this does not seem beneficial
for cancer cells, it might be that with the overall broad
effects of MYC, lncRNA-MIF is an additional factor
in fine-tuning the most optimal MYC levels.
3. MYC-regulated ncRNAs involved in
five important hallmarks of cancer
The C13ORF25 RNA also known as the primary tran-
script of the oncogenic miR-17~92 cluster was identi-
fied as being MYC-induced in 2005 (He et al., 2005;
O’Donnell et al., 2005). The induction of this cluster is
achieved by binding of MYC together with E2F1-3
transcription factors to its promoter (Sylvestre et al.,
2007; Woods et al., 2007). The miR-17~92 cluster has
two paralogs: the miR-106a~363 cluster and the miR-
106b~25 cluster (Tanzer and Stadler, 2004). The miR-
106b~25 cluster is also regulated by E2F1 in
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combination with MYC (Petrocca et al., 2008). In
2008, multiple MYC-repressed miRNAs were identi-
fied using a human and a mouse B-cell lymphoma
model (Chang et al., 2008). MYC represses expression
of specific pri-miRNAs by binding to their promoter
regions and recruitment of HDAC3 (miR-15a/16 clus-
ter) (Zhang et al., 2012a), HDAC3 and EZH2 (miR-
26a, miR-19, and miR-129) (Han et al., 2016; Zhang
et al., 2012b; Zhao et al., 2013), or DNMT3a (miR-
34a) (Craig et al., 2011). Repression of the members of
the let-7 family by MYC is regulated post-transcrip-
tionally by the MYC-induced RNA binding protein
Lin28B (Chang et al., 2009).
One of the first identified MYC-regulated lncRNAs
is CCAT1. While the CCAT1-L transcript variant is
specifically overexpressed in colorectal cancer, the
CCAT1-S variant is upregulated in many other can-
cers, including gastric carcinoma and colon cancer (He
et al., 2014; Yang et al., 2013a). By binding to the
E-box element in the promoter region of CCAT1,
MYC induces expression of CCAT1-S. As the short
transcript variant is most likely formed by 30 process-
ing of the long variant, MYC probably induces
expression of CCAT1-L, but this has not been proven.
Besides CCAT1 and CCAT2, six other colorectal can-
cer-associated MYC-regulated lncRNAs (MYCLos/
CCAT3-8) have been identified (Kim et al., 2015a,b).
Three of them are MYC-induced, and the other three
are MYC-repressed. In the last five years, many more
MYC-regulated lncRNAs have been identified
although for many their function has not yet been
identified (Hart et al., 2014; Winkle et al., 2015).
Below, we describe in more detail the MYC-regu-
lated miRNAs (Table 1 and Fig. 3) and lncRNAs
(Table 2 and Fig. 4) with a clear role in five main hall-
marks of cancer, that is, cell cycle progression, apopto-
sis, metabolism, angiogenesis, and metastasis.
3.1. Cell cycle progression
Nineteen MYC-induced ncRNAs have a role in cell
cycle progression. LncRNA-assisted stabilization of
transcripts (LAST) stimulates CCND1 expression by
stabilizing CCND1 mRNA together with CNBP (Cao
et al., 2017). MiR-378a-3p ensures CCND1 expression
by targeting mRNA encoding TOB2, which is a
repressor of CCND1 expression (Feng et al., 2011).
CASC11 (CARLo-7) promotes CCND1 transcription
by stabilizing the hnRNP-K mRNA, which leads to
an hnRNP-K-dependent enhanced nuclear accumula-
tion of b-catenin (Zhang et al., 2016b). This leads to
activation of WNT/b-catenin signaling, and the
subsequent induction of CCND1 transcription. The
MYC-induced lncRNA MY (VSP9D1-AS1) associates
with hnRNP-K and stimulates CDK6 mRNA transla-
tion by competing with miR-16-5p for binding to
CDK6 mRNA (Kawasaki et al., 2016). CDKN2B
transcription is repressed by lncRNA CCAT-6 upon
binding of this lncRNA to hnRNP-K (Kim et al.,
2015b). All three lncRNAs interacting with hnRNP-K
(CASC11, MYU, and CCAT-6) have been shown to
stimulate cell cycle progression in colon cancer. The
four lncRNAs HOTAIR, MYCLo-1, CCAT1-S, and
DANCR all repress CDKN1A transcription (Kim
et al., 2014, 2015b; Liu et al., 2013; Lu et al., 2018;
Ma et al., 2014). HOTAIR represses CDKN1A tran-
scription by recruiting EZH2 and inducing epigenetic
changes, while MYCLo-1 is assisted by HuR to
repress the transcription of CDKN1A. The mecha-
nisms by which CCAT1-S and DANCR repress
CDKN1A transcription are not yet known. Members
of the miR-17-5p seed family have been strongly impli-
cated in stimulation of cell cycle progression by target-
ing CDKN1A (Ivanovska et al., 2008; Kim et al.,
2009; Trompeter et al., 2011). Conversely, the same
seed family represses cell cycle progression by targeting
CCND1/2 transcripts (Trompeter et al., 2011; Yu
et al., 2008) and E2F1-3 transcripts (He et al., 2005;
Luan et al., 2018; O’Donnell et al., 2005; Trompeter
et al., 2011). This is consistent with the cell type-speci-
fic roles as oncomiR as well as tumor suppressor miR
that have been observed for individual members of the
miR-17-5p seed family (He et al., 2005; O’Donnell
et al., 2005). The MYC-induced lncRNA CONCR
plays a role during S-phase and is required for cell
division by regulating the activity of helicase DDX11,
which is involved in DNA replication and sister chro-
matid cohesion (Marchese et al., 2016). The MYC-
induced lncRNA MINCR promotes MYC-mediated
transcription of a selected set of cell cycle genes
(Doose et al., 2015), although there is some debate
about whether this lncRNA is a direct MYC-induced
lncRNA or not (Doose et al., 2015, 2016; Hart et al.,
2016). Besides, MINCR functions as a sponge for
miR-26a-5p to stimulate cell cycle progression (Wang
et al., 2016).
Eleven MYC-repressed ncRNAs inhibit cell cycle
progression, while one MYC-repressed miRNA stim-
ulates cell cycle progression. The CCND1-3 and
CCNE1-2 transcripts are targeted by let-7b-5p (John-
son et al., 2007), the miR-15-5p seed family (Bonci
et al., 2008; Wang et al., 2009; Xu et al., 2009),
miR-26a/b-5p (Kota et al., 2009; Zhu et al., 2012),
and miR-34a-5p (He et al., 2007; Pok et al., 2013;
Sun et al., 2008). In addition, these miRNAs and
miR-29a-c-3p target CDK4/6 transcripts (He et al.,
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2007; Johnson et al., 2007; Kawasaki et al., 2016;
Sun et al., 2008; Xu et al., 2009; Zhao et al., 2010;
Zhu et al., 2012). The RB1 transcript is targeted by
miR-26a-5p (Lopez-Urrutia et al., 2017), and the
E2F3 transcript is targeted by miR-195-5p, a mem-
ber of the miR-15-5p seed family (Xu et al., 2009).
Let-7b-5p targets the CDC25 transcript, which
results in reactivation of CDKs to enable cell cycle
progression (Hoffmann, 2000). Let-7b-5p also targets
CDC34, which is an ubiquitin-conjugating enzyme
that is involved in the degradation of Wee1, an inhi-
bitor of CDK1 (Legesse-Miller et al., 2009). The
miR-15-5p seed family members target TFAP4,
which results in repression of CDKN1A and
CDKN2A transcription and reduced p21 and p16
levels (Jackstadt et al., 2013a). MiR-200b-3p targets
the CDKN1B transcript, leading to reduced p27
levels and stimulation of cell cycle progression (Fu
et al., 2014). So, it seems not beneficial for cancer
cells that MYC represses miR-200b-3p. MYCLo-4
and MYCLo-6 both block G2 to M phase progres-
sion by stimulating growth arrest and GADD45A
expression, a critical regulator of G2 arrest (Kim
et al., 2015a). MYCLo-5 is involved in controlling S
to G2 phase progression, but the exact mechanism is
not yet known.
3.2. Apoptosis
Seven MYC-induced and eight MYC-repressed
ncRNAs influence the balance between pro- and anti-
apoptotic factors. The MYC-induced miR-19a/b-3p,
miR-20a-5p, miR-25-3p, and miR-92a-3p prevent
apoptosis by targeting the BIM transcript (Mogilyan-
sky and Rigoutsos, 2013; Petrocca et al., 2008; Xiao
et al., 2008). In addition, miR-19a/b-3p target tran-
scripts of the PTEN, PP2A, and AMPK genes, result-
ing in decreased levels of the downstream pro-
apoptotic proteins BAD, Puma, and Noxa (Mavrakis
et al., 2010; Mu et al., 2009; Olive et al., 2009).
CCAT1-S was shown to upregulate the expression of
Livin, which is a member of the inhibitor of apoptosis
protein family that can interact with caspases to pre-
vent apoptosis (Chen et al., 2017).
Many of the MYC-repressed miRNAs directly tar-
get anti-apoptotic factors; for example, miR-15a/16-5p
and miR-34a-5p target the BCL2 transcript (Bommer
et al., 2007; Bonci et al., 2008; Cimmino et al., 2005),
miR-122-5p targets the BCL2L2 transcript (Lin et al.,
2008; Wang et al., 2014), and miR-26b-5p and miR-
29b-3p target the MCL1 transcript (Jiang et al., 2015;
Mott et al., 2007). Moreover, by targeting the IL-6
transcript, miR-26a-5p represses STAT3 signaling,
Table 1. MYC-regulated miRNAs with a function related to important hallmarks of cancer.
Proven target gene(s)a Cellular processesb
MYC-induced
miR-9-5p CDH1, LIFR, SOCS5 Angiogenesis, metastasis
miR-17-5p BIM, CCND1/2, E2F1-3, CDKN1A, PTEN, TGFBR, VEGF Cell cycle progression, angiogenesis,
apoptosis, metastasis
miR-18-5p CTGF, SMAD4 Angiogenesis, metastasis
miR-19-3p AMPK, BIM, PP2A, PTEN, THBS1 Apoptosis, angiogenesis, metabolism
miR-25-3p BIM, USP28 Cell cycle progression
miR-378-3p TOB2 Cell cycle progression
miR-378a-5p SUFU, TUSC1 Angiogenesis
MYC-repressed
let-7-5p CCND2, CDC25, CDC34, CDK6, HMGA2 Cell cycle progression, metastasis
miR-15-5p AP4, BCL2, CCND1/E1, CDK6, E2F3, GLUT3, SMAD3, VEGF Cell cycle progression, apoptosis,
metabolism, angiogenesis
miR-23-3p GLS, LDHA/B, SMAD3-5 Metabolism, metastasis
miR-26-5p CCND2/E1-2, CDK6, E2F3, EZH2, IL-6, MCL1, PDHX, PTEN, RB1 Cell cycle progression, apoptosis, metabolism,
metastasis
miR-29-3p AKT3, CDK6, MCL1, MMPP2, VASH2, VEGF Cell cycle progression, apoptosis,
angiogenesis, metastasis
miR-30-5p LDHA, UBE3C Metabolism, MYC regulation
miR-34-5p BCL2, CCND1/E2, CDK4, CDK6, SNAI1, ZNF281 Cell cycle progression, apoptosis, metastasis
miR-122-5p BCL2L2, E2F1, TFDP2 Apoptosis
miR-129-5p PDK4 Metabolism
miR-200-3p AKT2, CDKN1B, CTNNB1, GIT2, ROCK2, VEGF, ZEB-1, ZEB-2 Cell cycle progression, angiogenesis, metastasis
aNot all members of the seed families target the proven target genes. bNot all target genes mentioned in column two are involved in the
cellular processes mentioned here.
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Fig. 3. MYC-regulated miRNAs involved in five important hallmarks of cancer. For each hallmark, the MYC-regulated miRNAs and their
protein targets involved in stimulation (green) or repression (red) of the respective hallmark are indicated.
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which results in reduced Bcl2 and Mcl1 expression
levels (Yang et al., 2013b). The effects of miR-26a-5p
can be antagonized by MYC-induced MINCR, which
functions as a sponge for this miRNA and prevent
apoptosis (Wang et al., 2016).
3.3. Metabolism
Three MYC-induced and eight MYC-repressed
ncRNAs are involved in the regulation of aerobic gly-
colysis, a feature of cancer cells. By targeting PTEN
and PP2K transcripts, miR-19a/b-3p enhances PI3K
activity (Mavrakis et al., 2010; Mu et al., 2009; Olive
et al., 2009). This results in phosphorylation of Akt by
PDK1, which stimulates glycolysis through multiple
mechanisms, such as increased expression of several
glucose transporters, activation of PFK1/2 (important
regulatory enzymes of glycolysis), and mTOR. To fur-
ther ensure high mTOR activity, miR-19a/b-3p also
targets AMPK, an inhibitor of mTOR activity (Bolster
et al., 2002; Mavrakis et al., 2010). MiR-106a-5p tar-
gets the E2F3 transcript, which results in repression of
the glucose metabolism (Luan et al., 2018). This is
antagonized by H19, which has been proposed to pro-
mote glucose metabolism by acting as a sponge for
miR-106a-5p. MIF influences the glycolytic activity by
sequestering miR-586, thereby preventing expression of
MYC target genes involved in glycolysis, that is,
GLUT1, LDHA, PKM2, and HK2 (Zhang et al.,
2016a).
miRNAs repressed by MYC typically inhibit high
metabolic activity. The initial uptake of glucose is reg-
ulated by miR-195-5p, which targets GLUT3 (Fei
et al., 2012). MiR-23a/b-3p targets the mRNA
Table 2. MYC-regulated lncRNAs with a function related to
important hallmarks of cancer.
Proven target gene(s) Cellular processesa
MYC-induced
BCYRN1 ↑ MMP2/9/13, VEGF Angiogenesis, metastasis
CASC11 ↑ HNRNPK Cell cycle progression
↓ WIF1 Metastasis






CCAT6 ↓ CDKN2B Cell cycle progression
CONCR ↑ DDX11 Cell cycle progression
DANCR ↓ CDKN1A, miR-33b-5p Cell cycle progression












LAST ↑ CCND1 Cell cycle progression
Linc00176 ↓ miR-9-5p, miR-185-5p Cell cycle progression
LncRNA-MIF ↓ miR-586-5p Metabolism
MINCR ↓ miR-26a-5p Cell cycle progression,
apoptosis, metastasis
MYCLo-1 ↓ CDKN1A Cell cycle progression
MYU ↑ CDK6 Cell cycle progression
SINGH12 ↑ MMP13 Metastasis
MYC-repressed
IDH1-AS1 ↑ IDH1 Metabolism
MYCLo-4 ↑ GADD45A Cell cycle progression
MYCLo-5 Unknown Cell cycle progression
MYCLo-6 ↑ GADD45A Cell cycle progression
↑ indicates induced/stabilized/activated by the lncRNA, and ↓ indi-
cates being repressed by the lncRNA. aNot all proven target genes
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Fig. 4. MYC-regulated lncRNAs involved in five important hallmarks of cancer. For each hallmark, the lncRNAs that are promoting or
inhibiting are indicated. Cell survival represents the opposite of apoptosis in this figure. LncRNAs highlighted in blue are MYC-induced,
lncRNAs highlighted in yellow are MYC-repressed, and lncRNAs in italic function as sponges for miRNAs.
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encoding GLS, which converts glutamine to glutamate
and thereby contributes to production of ATP (Gao
et al., 2009). In addition, miR-23a-3p targets LDH
subunits A and B (LDHA/LDHB), which convert the
glycolytic end product pyruvate to lactate (Poyyakkara
et al., 2018). Moreover, LDHA is also targeted by
miR-30a-5p (Chang et al., 2008; Li et al., 2017a).
MiR-26a-5p inhibits PDH activity by targeting PDHX
and therefore inhibits the conversion of pyruvate to
coenzyme A, an important component of the TCA
cycle (Chen et al., 2014a). Instead, pyruvate is con-
verted to lactate, showing an oncogenic role for miR-
26a-5p in metabolism. In contrast, miR-129 targets
PDK4 mRNA, thereby stimulating PDH activity (Han
et al., 2016). MYC-repressed lncRNA IDH1-AS1 stim-
ulates homodimerization of IDH1 by forming a tern-
ary structure with the enzyme, thereby enhancing its
activity (Xiang et al., 2018). IDH1 converts isocitrate
to a-ketoglutarate, which is an intermediate in the
TCA cycle and can inhibit glycolysis via degradation
of HIF1a under normoxic condition (MacKenzie
et al., 2007). By repressing IDH1-AS1, MYC downreg-
ulates IDH1 activity and ensures glycolysis.
3.4. Angiogenesis
Stimulation of angiogenesis by different mechanisms
has been reported for eight MYC-induced ncRNAs,
while five MYC-induced and four MYC-repressed
miRNAs inhibit angiogenesis by targeting pro-angioge-
netic factors. Angiogenesis is enhanced by repression
of the TGF-b signaling pathway. MiR-17-5p and miR-
20a-5p target the TGFBR2 transcript, while miR-18a-
5p targets the downstream effector SMAD4 (Dews
et al., 2010). Besides, several inhibitors of angiogenesis
are targeted; miR-19a-3p targets THBS1 (Dews et al.,
2010), miR-18a-5p targets CTGF (Ernst et al., 2010;
Fox et al., 2013), and miR-378-5p targets TUSC2 and
SUFU (Lee et al., 2007). VEGF expression is stimu-
lated directly by lncRNA BCYRN1 (Hu and Lu,
2015; Peng et al., 2018) and indirectly by miR-20a-5p
(Wang et al., 2017a). MiR-20a-5p targets PTEN,
which leads to increased VEGF levels via activation of
the PI3K/Akt pathway. In contrast, VEGF is inhibited
by miR-16-5p, miR-17-5p, miR-20a/b-5p, miR-29a-3p,
miR-106a/b-5p, and miR-200b-3p (Chen et al., 2014b;
Choi et al., 2011; Hua et al., 2006). In this context,
miR-200b-3p acts a tumor suppressor in contrast to its
oncogenic role in cell cycle regulation. MiR-29b-5p
indirectly lowers VEGF levels by targeting the Akt3
transcript (Li et al., 2017b). In melanoma cells, the
effect of miR-106a-5p on VEGF expression can be
counteracted by H19, which acts as a sponge for this
miRNA (Luan et al., 2018). At first sight, it seems
conflictive that both MYC-induced and MYC-
repressed miRNAs target VEGF mRNA. However, as
angiogenesis is crucial for a wide variety of physiologi-
cal and pathological processes, VEGF expression has
to be tightly regulated. This can be achieved by a com-
bination of several regulatory factors including MYC-
induced and MYC-repressed miRNAs, as well as other
ncRNAs ensuring optimal VEGF levels under various
conditions. MiR-29a-3p also targets the mRNA encod-
ing a second pro-angiogenetic factor, VASH2 (Jia
et al., 2016). VASH2 inhibition by miR-29a-3p can
also be antagonized by H19, which acts as a sponge
for miR-29a-3p in glioma microvessels and epithelial
cells (Jia et al., 2016).
3.5. Metastasis
Ten MYC-induced ncRNAs target metastasis-asso-
ciated genes. H19 promotes metastasis by recruitment
of EZH2 and the subsequent epigenetic suppression of
E-cadherin expression (Luo et al., 2013). Loss of E-
cadherin allows EMT, an early step in metastasis.
MiR-9-5p promotes metastasis by targeting E-cad-
herin, LIFR, and SOCS5 (Chen et al., 2012; Ma et al.,
2010; Zhuang et al., 2012). LIFR inhibits metastasis
through the Hippo/YAP pathway, and SOCS5 inhibits
endothelial cell migration by inhibiting the JAK/STAT
pathway. By interacting with EZH2, CASC11 and
HOTAIR epigenetically suppress Wif1 expression and
ensure stimulation of metastasis by the Wnt/b-catenin
pathway (Ge et al., 2013; Zhang et al., 2016b). As
described in the paragraph above, three members of
the miR-17-5p seed family target genes involved in the
TGFb signaling pathway, a crucial pathway also for
the induction of metastasis. BCYRN1 stimulates
metastasis by inducing the expression of MMP2,
MMP9, and MMP13 (Hu and Lu, 2015; Peng et al.,
2018). SNHG12 is a second lncRNA that induces the
expression of MMP13 (Wang et al., 2017b). In con-
trast to BCYRN1 that induces MMP13 transcription,
SNHG12 enhances MMP13 expression at the post-
transcriptional level.
Ten MYC-repressed miRNAs prevent metastasis,
while one MYC-repressed miRNA can both induce
and prevent metastasis, depending on the cell type.
The transcription factors SNAI1/2, ZEB1/2, Twist,
and AP4 all repress E-cadherin expression at the tran-
scriptional level (Tania et al., 2014). MiR-34a-5p tar-
gets the SNAI1 transcript directly and indirectly by
targeting the Kr€uppel-type transcription factor
ZNF281 transcript (Hahn et al., 2013). In addition to
being repressed by MYC, miR-34a is also repressed by
36 Molecular Oncology 13 (2019) 26–45 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
MYC and non-coding RNA crosstalk in cancer L. J. Y. M. Swier et al.
HOTAIR upon interaction with EZH2, thereby pro-
moting metastasis in gastric cancer cells (Liu et al.,
2015b). Let-7a/b/e-5p repress SNAI1 and SNAI2
expression indirectly by targeting the chromatin
remodeling HMGA2 transcript (Lee and Dutta, 2007;
Mayr et al., 2007). This is counteracted by CCAT1-S
functioning as a sponge for let-7 family members let-
7a/b/c/e-5p (Deng et al., 2015). CCAT1-S can also
sequester miR-148a-3p in osteosarcoma cells, thereby
stimulating invasion and migration via unknown
mechanisms (Zhao and Cheng, 2017). ZEB1/2 tran-
scripts are targeted by miR-200a-c-3p (Korpal et al.,
2008; Park et al., 2008). The miR-15a-5p seed family
targets mRNA encoding AP4, which induces SNAI1
expression (Jackstadt et al., 2013b). The role of miR-
26a-5p with respect to metastasis seems to be contra-
dictory. By targeting PTEN mRNA, miR-26a-5p stim-
ulates the Akt/NFjB pathway and thereby induces
expression of Twist, b-catenin, and MMP2 in lung
cancer (Liu et al., 2012). Increased levels of b-catenin
will initiate Wnt signaling, which stimulates metastasis.
MMP2 is an essential protease involved in adhesion,
invasion, and migration by proteolytic degradation of
type IV collagen. In contrast, by targeting IL-6 in hep-
atocellular carcinoma, miR-26a-5p represses STAT3
signaling and this results in lower MMP2 levels (Yang
et al., 2013b). Furthermore, MMP2 is also targeted by
miR-29b-3p (Fang et al., 2011). miRNAs that repress
metastasis by repressing the downstream SMAD pro-
teins of the TGFb signaling pathway are miR-23b-3p
(SMAD3-5) (Rogler et al., 2009) and miR-195-5p
(SMAD3) (Zhou et al., 2016). MiR-200a-3p targets
the mRNA encoding b-catenin in colorectal cancer,
thereby repressing metastasis (Yang et al., 2017).
Another pathway involved in metastasis by influencing
cell motility is the Rho/ROCK signaling pathway,
which is repressed by targeting of ROCK2 and GIT2
transcripts by miR-200b/c-3p (Peng et al., 2013; Wong
et al., 2015; Zhou et al., 2017). All repressing effects
of the miR-200 seed family can be antagonized by
H19, which functions as a sponge for these miRNAs
(Li et al., 2016; Liang et al., 2015; Yang et al., 2017;
Zhou et al., 2017). Besides, MINCR stimulates metas-
tasis by sequestering miR-26a-5p (Wang et al., 2016).
4. Discussion
It is evident that an extensive, multilayered ncRNA
network exists around MYC with critical roles for
multiple lncRNAs and miRNAs in crucial cellular pro-
cesses and in tumorigenesis. The picture that we pre-
sent here is most likely still far from complete, as
functions of most of the MYC-regulated ncRNAs are
not known yet (Hart et al., 2014; Robertus et al.,
2010; Winkle et al., 2015). It is clear that many miR-
NAs and lncRNAs regulate MYC and that they can
do this via diverse mechanisms at the level of tran-
scription, translation, protein stability, and functional-
ity. This suggests that redundancy is important to
ensure optimal MYC levels and thereby cell viability
under various conditions, as well as in different cell
types. As MYC is involved in many cellular processes
in redundant ways, it is remarkable that repression or
reintroduction of a single MYC-regulated ncRNA can
already show strong effects on MYC-associated phe-
notypes, as has been shown for many ncRNAs
described in this review.
Expression of lncRNAs was shown to be more cell
type specific than that of protein-coding genes (Derrien
et al., 2012). Also compared to miRNAs, lncRNAs
appear to be more cell type-specific. However, this
might be biased as there are many more lncRNAs
than miRNAs, which increases the chance to find cell
type-specific lncRNAs. Based on current knowledge, it
seems that the cell type-specific expression of certain
lncRNAs can influence the output of MYC in two
ways. First, cell type-specific lncRNAs can influence
important cellular processes downstream of MYC
(Fig. 4). Second, other cell type-specific lncRNAs, like
PCGEM1 and PDIA3P, can modulate binding effi-
ciency of MYC to promoters of a specific set of genes.
So, these lncRNAs may direct the cell type-specific tar-
get gene repertoire of MYC, rather than MYC acting
as a general amplifier of expression. Altogether, a pic-
ture is emerging that lncRNAs guide cell type-specific
effects of MYC.
Although MYC has a central role in tumorigenesis,
no effective MYC-specific drugs are being employed in
the clinic to date. Given the crucial functions of multiple
lncRNAs and miRNAs in the oncogenic MYC network,
it is tempting to speculate that targeting of ncRNAs
within the MYC network might be an alternative to
explore novel anticancer therapies. These ncRNAs can
have profound impacts on MYC levels and activity and
can also act downstream of MYC enabling cancer cells
to gain the crucial hallmarks of cancer. To allow selec-
tion of the most optimal ncRNA targets, a more system-
atic analysis of their functional networks in normal cells
as well as in cancer cells needs to be performed to over-
see the consequences of targeting them.
Currently, more and more institutes and companies
investigate how to specifically target miRNAs and
lncRNAs, using both antisense and small molecule-
based strategies (Chakraborty et al., 2017; Warner
et al., 2018). Inhibitors for miR-92 and miR-122, as
well as mimics of miR-16, miR-29 and miR-34, have
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been developed and tested or are currently tested in
clinical trials (NIH U.S. National Library of Medicine,
https://clinicaltrails.gov/ (accessed 06.08.2018)). As
miR-34a-5p has tumor suppressor activity by both tar-
geting MYC and stimulating apoptosis, while repress-
ing cell cycle progression and metastasis, it is an
attractive target for novel anticancer therapies. MiR-
16-5p and miR-29-3p too have tumor-suppressive roles
in four of the five hallmarks discussed and form
attractive targets as well. The cell type-specific expres-
sion of lncRNAs adds to their attractiveness as targets
for therapy (Derrien et al., 2012). The choice for an
attractive target will therefore depend on the type of
cancer. For example, CCAT1-L and CCAT2 form
attractive targets to specifically inhibit MYC transcrip-
tion in colorectal cancer. A drug against CCAT1-L,
which will also target CCAT1-S, would be very inter-
esting as it will inhibit cell cycle progression and
metastasis, while promoting apoptosis. However, a
main problem for testing effectivity of lncRNA-based
drugs is the limited conservation for many of the
lncRNAs, which prevents pre-clinical experiments in
relevant mouse models. Patient-derived xenotransplan-
tation models or organoid cultures might represent an
alternative approach to test effectiveness of targeting
human-specific lncRNAs.
Thus, although MYC is described as one of the
most important oncogenes, it is important to realize
that there is an extensive, multilayered ncRNA net-
work around MYC, in which intricate crosstalk con-
tributes to hallmarks of cancer.
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